XTLB vs NRXP vs SIGA vs BFRI vs AEYE

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +1. 4%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SIGA Technologies, Inc.

(SIGA) is the lower-risk stock at 1. 15β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 99% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 59% for Biofrontera Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, BFRI leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SIGA Technologies, Inc.

(SIGA) is the more profitable company, earning 24. 6% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SIGA (12.

7% yield) pays a dividend. XTLB, NRXP, BFRI, AEYE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XTLB (Healthcare) and NRXP (Healthcare) and SIGA (Healthcare) and BFRI (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XTLB is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; BFRI is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. SIGA pays a dividend while XTLB, NRXP, BFRI, AEYE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.